The F423Y mutation in the pfmdr2 gene and mutations N51I, C59R, and S108N in the pfdhfr gene are independently associated with pyrimethamine resistance in Plasmodium falciparum isolates

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2750-2752

  Briolant, Sébastien ^a   Bogreau, Hervé ^a   Gil, Marine ^a   Bouchiba, Housem ^a   Baret, Eric ^a,b   Amalvict, Rémy ^a,b   Rogier, Christophe ^a,c   Pradines, Bruno ^a,b  

^a INSTITUT DE RECHERCHE BIOMÉDICALE DES ARMÉES   (France)

^b Centre National de Reference du Paludisme   (France)

^c INSTITUT PASTEUR DE MADAGASCAR   (Madagascar)

Author keywords

[No Author keywords available]

Indexed keywords

PFDHFR PROTEIN; PFMDR2 PROTEIN; PROTEIN; PYRIMETHAMINE; UNCLASSIFIED DRUG;

ARTICLE; GENE MUTATION; GENE SEQUENCE; HUMAN; IN VITRO STUDY; NONHUMAN; PARASITE ISOLATION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIMALARIALS; DRUG RESISTANCE; FOLIC ACID ANTAGONISTS; GENES, PROTOZOAN; HUMANS; LOGISTIC MODELS; MALARIA, FALCIPARUM; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MULTIVARIATE ANALYSIS; MUTATION; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PYRIMETHAMINE; SEQUENCE ANALYSIS, DNA; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 84860210470     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05618-11     Document Type: Article

References (21)

1. Auliff A, et al. 2006. Amino acid mutations in Plasmodium vivax DHFR and DHPS from several geographical regions and susceptibility to antifolate drugs. Am. J. Trop. Med. Hyg. 75:617- 621.
2. Basco LK, Ramiliarisoa O, Le Bras J. 1994. In vitro activity of pyrimethamine, cycloguanil, and other antimalarial drugs against African isolates and clones of Plasmodium falciparum. Am. J. Trop. Med. Hyg. 50:193-199. (Pubitemid 24079426)
3. Bojang KA, et al. 2011. Two strategies for the delivery of IPTc in an area of seasonal malaria transmission in the Gambia: a randomised controlled trial. PLoS Med. 8:e1000409.
4. Dahlström S, Veiga MI, Martensson A, Bjorkman A, Gil JP. 2009. Polymorphism in PfMRP1 (Plasmodium falciparum multidrug resistance protein 1) amino acid 1466 associated with resistance to sulfadoxinepyrimethamine treatment. Antimicrob. Agents Chemother. 53:2553-2556.
5. Ekong RM, Robson KJ, Baker DA, Warhurst DC. 1993. Transcripts of the multidrug resistance genes in chloroquine-sensitive and chloroquineresistant Plasmodium falciparum. Parasitology 106(Pt. 2):107-115. (Pubitemid 23038209)
6. Griffin JT, et al. 2010. Protective efficacy of intermittent preventive treatment of malaria in infants (IPTi) using sulfadoxine-pyrimethamine and parasite resistance. PLoS One 5:e12618.
7. Hawkins VN, Joshi H, Rungsihirunrat K, Na-Bangchang K, Sibley CH. 2007. Antifolates can have a role in the treatment of Plasmodium vivax. Trends Parasitol. 23:213-222. (Pubitemid 46621225)
8. Le Port A, et al. 2011. Prevention of malaria during pregnancy: assessing the effect of the distribution of IPTp through the national policy in Benin. Am. J. Trop. Med. Hyg. 84:270 -275.
9. Lu F, et al. 2010. Mutations in the antifolate-resistance-associated genes dihydrofolate reductase and dihydropteroate synthase in Plasmodium vivax isolates from malaria-endemic countries. Am. J. Trop. Med. Hyg. 83:474-479.
10. Martinelli A, Henriques G, Cravo P, Hunt P. 2011. Whole genome re-sequencing identifies a mutation in an ABC transporter (mdr2) in a Plasmodium chabaudi clone with altered susceptibility to antifolate drugs. Int. J. Parasitol. 41:165-171.
11. Parola P, et al. 2007. Antimalarial drug susceptibility and point mutations associated with drug resistance in 248 Plasmodium falciparum isolates imported from Comoros to Marseille, France in 2004 2006. Am. J. Trop. Med. Hyg. 77:431- 437.
12. Parzy D, et al. 1997. Proguanil resistance in Plasmodium falciparum African isolates: assessment by mutation-specific polymerase chain reaction and in vitro susceptibility testing. Am. J. Trop. Med. Hyg. 57:646-650. (Pubitemid 28049377)
13. Peel SA. 2001. The ABC transporter genes of Plasmodium falciparum and drug resistance. Drug Resist. Updat. 4:66 -74.
14. Rosenberg E, et al. 2006. pfmdr2 confers heavy metal resistance to Plasmodium falciparum. J. Biol. Chem. 281:27039 -27045.
15. Rubio JP, Cowman AF. 1994. Plasmodium falciparum: the pfmdr2 protein is not overexpressed in chloroquine-resistant isolates of the malaria parasite. Exp. Parasitol. 79:137-147.
16. Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y, Santi DV. 1997. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc. Natl. Acad. Sci. U. S. A. 94:1124 -1129.
17. Tjitra E, Baker J, Suprianto S, Cheng Q, Anstey NM. 2002. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquinesulfadoxine- pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob. Agents Chemother. 46: 3947-3953. (Pubitemid 35403273)
18. Triglia T, Wang P, Sims PF, Hyde JE, Cowman AF. 1998. Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria. EMBO J. 17:3807-3815. (Pubitemid 28333967)
19. World Health Organization. 2006, posting date. WHO guidelines for the treatment of malaria in travellers, chapters 7 (section 9.4) and 8. World Health Organization, Geneva, Switzerland. http://www.who.int/malaria/docs/ TreatmentGuidelines2006.pdf.
20. Wurtz N, et al. 2010. Synergy of mefloquine activity with atorvastatin, but not chloroquine and monodesethylamodiaquine, and association with the pfmdr1 gene. J. Antimicrob. Chemother. 65:1387-1394.
21. Zalis MG, Wilson CM, Zhang Y, Wirth DF. 1994. Characterization of the pfmdr2 gene for Plasmodium falciparum. Mol. Biochem. Parasitol. 63: 311.